Generics 38

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Abiraterone manufacturers

38 products found

Filters

38 products found

abiraterone

Tablets 250 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
FDA, EU GMP, ANVISA, Libya, Saudi Arabia, South Korea
Unavailable markets
United States , Algeria , Bahrain , Djibouti , Egypt , Iran , Iraq , Israel , Jordan , Kuwait , Lebanon , Libya , Malta , Morocco , Oman , Qatar , Saudi Arabia , Syria , Tunisia , United Arab Emirates , Yemen , Ethiopia , Sudan , Vietnam
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 9 days

abiraterone

Tablets, film coated 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Zytiga®
Manufacturer #252
This company is a leading player in the pharmaceutical industry, boasting decades of experience in research, development, and manufacturing. They specialize in the production of a wide range of pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for both human and veterinary use. Their product portfolio spans multiple therapeutic areas, including but not limited to, oncology, cardiology, and other essential therapeutic categories. They offer a comprehensive range of services, including contract manufacturing (CMO) and the production of over-the-counter (OTC) products. The company holds EU and US GMP approvals for its production lines, ensuring adherence to rigorous quality standards. Their production lines encompass various dosage forms, including solids, liquids, and injectables. Their global presence extends across Europe and North America, with a network of 10 manufacturing facilities. They have a strong commitment to research and development, with dedicated teams focusing on innovative solutions and advancements in the pharmaceutical field.

Manufacturer usually replies in 12 days

abiraterone

Tablets, film coated 500 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #419

The manufacturer based in Europe, has decades of experience in the industry. They focus on a diverse range of products, including prescription drugs, over-the-counter medications, and medical devices. Their portfolio covers a variety of therapeutic areas, with key focuses on cardiovascular health, oncology, and pain management. The manufacturer holds numerous patents for their innovative products and adheres to strict GMP standards for both the European Union and the United States. They distribute their products across key regions in Europe, North America, and other international markets. Their production lines include solid oral dosage forms, injectables, and liquids, offering a wide range of treatment options for patients.

Manufacturer usually replies in 5 days

Want to see all 38 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Abiraterone acetate Manufacturers

Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication. Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer. Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world. Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from: Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication. it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of <2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced. Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include: severe baseline hepatic impairment, mineralocorticoid excess, cardiovascular disease like heart failure and hypertension, uncorrected hypokalemia,

How Does Abiraterone acetate Work?

Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.

The Wholesale Price of Abiraterone acetate

The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.

Sourcing Abiraterone Manufacturers and Abiraterone acetate Suppliers

Those who are looking for an easy and convenient way to source and order abiraterone may search online using Pipelinepharma's marketplace. Through our strict evaluation and quality control process, you are assured to find verified abiraterone manufacturers and suppliers.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation